Silexion Therapeutics Is A Pioneering Clinical Stage Oncology Focused Biotechnology Company Engaged In Discovering And Developing Proprietary Treatments For Kras Driven Cancersthe Company S Platform Technology Is Addressing Difficult To Treat Solid Tumorssilexion S Lead Product Candidatesil 204Consists Of Locally Administered Small Interfering Rnasor Sirnain An Extended Release Formulationas A First Line Treatment Of Locally Advanced Pancreatic Cancer Patients Combined With Standard Of Care Chemotherapysil 204 Is A Sirna Product Candidate Following Phase 1 And Phase 2 Clinical Trials With Silexion S First Generation Sig12D Loderalso Referred To As Lodera Cresults From The Lodera C Phase 2 Clinical Trial Showed A Trend For Differences Between Treatment Groups With The Loder Arm Suggesting An Overall Survival Advantage Of 9 3 Monthssilexion Commitment To Pushing The Boundaries Of Therapeutic Advancements In The Field Of Oncology Is Focused On Its Second Generation Microparticle Delivery Systemsil 204 A Newly Formulated Product That Will Improve Clinical Efficacysilexion Plans To Conduct A Phase 2 3 Trial Of Sil 204 In Locally Advanced Pancreatic Cancer Patients That Harbor The Kras G12D And G12V Mutations Silexion Therapeutics Ltdis Headquartered In Israel And Partnered With Well Known Gmp Compliant Sirna Facilitylgc Axolabs Group Located In Petaluma Californiaand Worldwide Experts Extended Release Formulation Facilityevonik Corporation Located In Birminghamalabama To Upscale Manufacturing
No conferences found for this company.
| Company Name | Silenseed Ltd |
| Country |
Israel
|
| Address | N/A |
| Telephone | N/A |
| N/A |
